Final results of a phase I intermittent dose-escalation trial of ZD1839 (“Iressa”) in Japanese patients with various solid tumours [abstract 1292] - Negoro,S.; Nakagawa,K.; Fukuoka,M. (Proc Am Soc Clin Oncol, 2001)